{
    "clinical_study": {
        "@rank": "32045", 
        "brief_summary": {
            "textblock": "Anidulafungin may be effective for the treatment of invasive Candida infections.  The\n      purpose of the study is to find the balance between dose tolerance and effectiveness of\n      several doses for the treatment of United States patients with invasive candidiasis."
        }, 
        "brief_title": "The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.", 
        "completion_date": {
            "#text": "November 2002", 
            "@type": "Actual"
        }, 
        "condition": "Candidiasis", 
        "condition_browse": {
            "mesh_term": [
                "Candidiasis", 
                "Candidiasis, Invasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Positive culture plus at least one clinical sign and symptom consistent with\n             invasive candidiasis preferably within 96 hours of the proposed first dose of study\n             drug\n\n          -  Life expectancy: greater than 72 hours\n\n        Exclusion Criteria:\n\n          -  Pregnant Females\n\n          -  Treatment with other investigational drug(s) within 4 weeks\n\n          -  Hypersensitivity to anidulafungin or echinocandin therapy\n\n          -  Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00037219", 
            "org_study_id": "VER002-6", 
            "secondary_id": "A8851018"
        }, 
        "intervention": {
            "intervention_name": "Anidulafungin, VER002", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anidulafungin", 
                "Echinocandins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "Anidulafungin", 
            "Candidemia", 
            "Invasive Candidiasis"
        ], 
        "lastchanged_date": "October 17, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "King of Prussia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19406"
                }, 
                "name": "Versicor, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase 2, Open-Label, Randomized, Dose-Ranging Study of the Safety and Efficacy of Intravenous Anidulafungin (VER002) in the Treatment of Patients With Invasive Candidiasis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037219"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "collaborator": {
                "agency": "Vicuron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2008"
    }, 
    "geocoordinates": {
        "Versicor, Inc.": "40.089 -75.396"
    }
}